Trial · NCT02520102
Open Label Study of Sargramostim Among Patients Receiving Myelosuppressive Induction Chemotherapy for Acute Myelogenous Leukemia
NCT02520102, Phase 2, Withdrawn, Sanofi
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Open Label Study of Sargramostim Among Patients Receiving Myelosuppressive Induction Chemotherapy for Acute Myelogenous Leukemia. Trials, record NCT02520102. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02520102
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Open Label Study of Sargramostim Among Patients Receiving Myelosuppressive Induction Chemotherapy for Acute Myelogenous Leukemia
- NCT number
- NCT02520102
- Status
- Withdrawn
- Phases
- Phase 2
- Enrollment
- 0 participants, actual
- Lead sponsor
- Sanofi
- Conditions
- Acute Myeloid Leukemia NOS
- Interventions
- sargramostim GZ402664
- First posted
- 2015-08-11
- Last updated
- 2017-04-20
Source ClinicalTrials.gov
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Proportion of patients who develop antibodies (binding antibodies and neutralizing antibodies) | 1 month after 1st dose of sargramostim | |
| Primary | Proportion of patients who develop antibodies (binding antibodies and neutralizing antibodies) | 2 months after 1st dose of sargramostim | |
| Primary | Proportion of patients who develop antibodies (binding antibodies and neutralizing antibodies) | 3 months after 1st dose of sargramostim | |
| Primary | Proportion of patients who develop antibodies (binding antibodies and neutralizing antibodies) | 6 months after 1st dose of sargramostim. If positive at month 6, this will be continued every 6 months until the values return to baseline or up to 24 months | |
| Secondary | Assessment of antibodies (antibody detection and antibody titers) | 1 month after 1st dose of sargramostim | |
| Secondary | Assessment of antibodies (antibody detection and antibody titers) | 2 months after 1st dose of sargramostim | |
| Secondary | Assessment of antibodies (antibody detection and antibody titers) | 3 months after 1st dose of sargramostim | |
| Secondary | Assessment of antibodies (antibody detection and antibody titers) | 6 months after 1st dose of sargramostim. If positive at month 6, this will be continued every 6 months until the values return to baseline up to 24 months | |
| Secondary | Assessment of immunoglobulin levels | 1 month after 1st dose of sargramostim | |
| Secondary | Assessment of immunoglobulin levels | 2 months after 1st dose of sargramostim |
1 to 10 of 14Source ClinicalTrials.gov
See all 14 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02520102
GET https://conductscience.org/api/trials/v1/NCT02520102/registered